Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman has maintained an Outperform rating on RxSight (NASDAQ:RXST) and increased the price target from $50 to $54.
January 29, 2024 | 6:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Steven Lichtman reaffirmed an Outperform rating on RxSight and raised the price target from $50 to $54, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Steven Lichtman suggests a strong conviction in RxSight's future performance. This typically instills confidence in current and potential investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100